Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, N.
Right arrow Articles by Taylor, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, N.
Right arrow Articles by Taylor, P. R.
Clinical Cancer Research Vol. 10, 6013-6022, September 15, 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Comprehensive Characterization of Annexin I Alterations in Esophageal Squamous Cell Carcinoma

Nan Hu1, Michael J. Flaig2, Hua Su1, Jian-Zhong Shou3, Mark J. Roth4, Wen-Jun Li4, Chaoyu Wang1, Alisa M. Goldstein5, Guang Li4, Michael R. Emmert-Buck6 and Philip R. Taylor1

1 Cancer Prevention Studies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; 2 Klinik und Poliklinik fur Dermatologie und Allergologie der Ludwig-Maximilians-Universitat Munchen, Munich, Germany; 3 Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 4 Shanxi Cancer Hospital, Taiyuan, Shanxi, People’s Republic of China; 5 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland; and 6 Pathogenetics Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

ABSTRACT

Purpose: The purpose is to characterize alterations of the annexin I gene, its mRNA, and protein expression in esophageal squamous cell carcinoma.

Experimental Design: Fifty-six cases of esophageal squamous cell carcinoma were analyzed using four microsatellite markers flanking the annexin I gene (9q11-q21) to identify loss of heterozygosity. In addition, we performed (a) single-strand conformation polymorphism and DNA sequencing along the entire promoter sequence and coding region to identify mutations, (b) real-time quantitative reverse transcription-PCR of RNA from frozen esophageal squamous cell carcinoma tissue (n = 37) and in situ hybridization (n = 5) on selected cases to assess mRNA expression, and (c) immunohistochemistry (n = 44) to evaluate protein expression. The prevalence of the allelic variants identified in the first 56 patients was refined in 80 additional esophageal squamous cell carcinoma patients and 232 healthy individuals.

Results: Forty-six of 56 (82%) esophageal squamous cell carcinoma patients showed loss of an allele at one or more of the four microsatellite markers; however, only one (silent) mutation was seen. Two intragenic variants were identified with high frequency of allelic loss (A58G, 64%; L109L, 69%). Thirty of 37 (81%) esophageal squamous cell carcinoma patients showed reduced annexin I mRNA expression, which was confirmed by in situ hybridization, whereas annexin I protein expression was reduced in 79% of poorly differentiated tumor cell foci but in only 5% of well-differentiated tumor foci, although allelic loss on chromosome 9 was found in both tumor grades.

Conclusions: Allelic loss of annexin I occurs frequently, whereas somatic mutations are rare, suggesting that annexin I is not inactivated in esophageal squamous cell carcinoma via a two-hit mechanism. A decrease in annexin I protein expression was confirmed, consistent with a quantitative decrease in mRNA expression, and appeared to be related to tumor cell differentiation. We conclude that annexin I is not the tumor suppressor gene corresponding to the high levels of loss of heterozygosity observed on chromosome 9 in esophageal squamous cell carcinoma; however, dysregulation of mRNA and protein levels is associated with this tumor type.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Sakaguchi, H. Murata, H. Sonegawa, Y. Sakaguchi, J.-i. Futami, M. Kitazoe, H. Yamada, and N.-h. Huh
Truncation of Annexin A1 Is a Regulatory Lever for Linking Epidermal Growth Factor Signaling with Cytosolic Phospholipase A2 in Normal and Malignant Squamous Epithelial Cells
J. Biol. Chem., December 7, 2007; 282(49): 35679 - 35686.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
L. H. K. Lim and S. Pervaiz
Annexin 1: the new face of an old molecule
FASEB J, April 1, 2007; 21(4): 968 - 975.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. L. Wang, T.-T. Wu, E. Resetkova, H. Wang, A. M. Correa, W. L. Hofstetter, S. G. Swisher, J. A. Ajani, A. Rashid, S. R. Hamilton, et al.
Expression of Annexin A1 in Esophageal and Esophagogastric Junction Adenocarcinomas: Association with Poor Outcome
Clin. Cancer Res., August 1, 2006; 12(15): 4598 - 4604.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.